Zoledronic Acid Prevents Bone Loss in Premenopausal Breast-Cancer Patients Zoledronic Acid Prevents Bone Loss in Premenopausal Breast-Cancer Patients

Zoledronic acid can prevent treatment-related bone loss in premenopausal breast-cancer patients, and the benefit persists for up to three years after treatment, according to new findings.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news